Global Chronic Idiopathic Constipation drug market is estimated to grow with approx.8.42% CAGR during the year 2018 – 2026. The base year considered for the study is 2017 and the forecast period is 2018-2026. The global CIC drug market is primarily driven by the following factors:

• Modern dietary habits taking a toll on the health
• Cancer or other systematic diseases can lead to CIC
• Increasing elderly population
• Improved and efficient drugs in the pipeline
• Increasing constipation problems due to side effects of prescribed medicines

To know more about this report, request a free sample copy.

The important driver increasing growth in the global chronic idiopathic constipation drug market are modern dietary habits that are having adverse effects on the human body. Some of the dietary habits leading to constipation are intake of foods rich in animal fats especially dairy products, eggs and meat or foods that have refined sugar and low fibre. Also, inadequate fluid intake leads to the deficiency of water in the colon which leads to the problems in keeping the stool soft. Excessive intake of caffeine and alcohol increases excretion and thus urination of water. This leads to dehydration because of the increase in water absorption from the intestine. As a result, not enough fluid is retained in the stool, and this leads to constipation.

Over-the-counter (OTC) drugs are medicines which can be bought without a prescription from a doctor. Many different kinds of OTC laxatives are available. Some constipation medicines may be called stool softeners or fibre supplements. Constipation includes infrequent bowel movements with stools that are hard and sometimes painful to pass. Over-the-counter fibre products such as psyllium (brand name Metamucil), polycarbophil (FiberCon) and methylcellulose (Citrucel) are usually the best first choice for constipation. They enable the intestine to contract due to stimulation caused by the drug.

Surgical treatments, unawareness and ignorance among the people are the major factors hindering the CIC drug market. CIC drugs are the non-surgical methods to get rid of chronic constipation. Many times, due to certain reasons such as infectivity of the drugs taken or the possible side effects, some doctors move towards surgical treatments of constipation. These surgical treatments of chronic constipation can be a big threat to chronic idiopathic constipation drugs market. Most of the people are unaware of constipation as a disease, while those aware may ignore to take proper medications for the disease. This is again creating a huge restraint for the growth of the market. Along with this, the side effects of CIC drugs is another major challenge.

The global CIC drug market segments include drug type and prescription type.

Drug types are as follows:

• Lubiprostone,
• Linaclotide
• Others

Prescription types are as follows:

• Prescribed drugs
• Over the Counter

The report scope is widely categorized on the basis of its drug types which include Lubiprostone, Linaclotide and others. Moreover, the market revenue estimates and forecasts include only drugs and exclude the surgical method.

Geographically, the global smart security market has been segmented on the basis of four major regions, which include:

• North America  Cic Drug Market – U.S. & Canada
• Asia Pacific Cic Drug Market – China, Japan, India, South Korea, Australia and RoAPAC
• Europe  Cic Drug Market – UK, Germany, France, Italy, Spain, and RoE
• Rest of World – MENA and Latin America.

North America is anticipated to dominate the global CIC drugs market throughout the forecast period. North America has two of the most developed nations in the world. The US and Canada have the most developed healthcare systems and medical devices industry in the world. Federal agencies and private firms equally participate in providing access to best medical facilities to the consumers. In North America, the issue of constipation is very common and found in approximately 28% of the population residing there. The condition is chronic, and the increasing prevalence of this CIC is very much there in the population, including women and nonwhites. The drug market has steady growth in this region as the government is continuously involved in taking initiatives and steps to treat and to improve the healthcare segment of the society by providing latest technological and advance medication treatments support. Growing lifestyle oriented diseases, increase in healthcare spending and technological advancement in cardiology are the factors responsible for the growth of this market. On the other hand, the Asia Pacific is considered to be the most promising and lucrative market and is expected to grow at the fastest rate during the forecast period. APAC is an emerging region with a huge scope for the pharmaceutical companies. Japan and China, in particular, are considered to be very promising countries for the various drug market. Since Asia is home to half of the world’s population and offers both, a relatively low-cost workforce in some countries and a potentially huge retail market, this region could be central to the future of the global economy.

The CIC drug market is segmented based on drug types (which is sub-divided into Lubiprostone, Linaclotide and others) and also on the basis  of prescription types (which is sub-divided into prescribed drugs and over the counter drugs).

The major market players in the global CIC drug market are:

• Synergy Pharmaceuticals
• Allergens
• Roche Holding Ag
• Pfizer
• Sucampo Pharmaceuticals Inc
• Others

Company Profiles covers analysis of important players

These companies are using organic and inorganic strategies for growth. For instance, Allergan announced  a collaboration with AstraZeneca to develop and commercialize ATM-AVI (aztreonam and avibactam) for antibiotic-resistant gram-negative infections.  Also, Roche holding Inc acquired Ariosa Diagnostics Inc, a privately held company based in California, US. Ariosa Diagnostics Inc is a molecular diagnostics testing service provider that provides non-invasive prenatal testing (NIPT) service using cell-free DNA (cfDNA) technology.

Key findings of the global smart security market.

• Modern dietary habits, increasing elderly population and improved and efficient drugs in the pipeline are fueling growth in the global CIC drug market.
• North America accounted for the largest revenue share in 2017.
• Over the counter segment is dominating the market, as doctor’s prescription is not required to buy the drugs
• Increasing government support
• Product launch is the key strategy adopted by various market players of the global CIC drug market
• Linaclotide is a major type of drug.